Navigation Links
Clinverse, Inc. Introduces ClinSpend to Meet Challenges of Sunshine Act Reporting Requirements
Date:6/5/2013

Raleigh, NC (PRWEB) June 05, 2013

Clinverse, Inc., a global technology and financial services company for clinical trials, today introduced its ClinSpend™ solution, designed to meet the reporting requirements to the Center for Medicare and Medicaid Services (CMS) for the federally mandated Sunshine Act, now called OPEN PAYMENTS, providing greater transparency around the financial relationships of manufacturers, physicians, and teaching hospitals.

ClinSpend is the aggregate spend reporting module within the family of products integrated seamlessly alongside Clinverse’s Financial Lifecycle System (FLS). ClinPay®, the company’s anchor product, is the industry’s leading fully-automated investigator payment system which streamlines and automates the financial payment process in clinical trials. For sponsors, clinical research organizations (CROs), and healthcare providers (HCPs) deploying ClinPay for payments, more than 90% of the research transactional data required by OPEN PAYMENTS already resides within the system. By leveraging the unified FLS platform, ClinSpend has the added capability to collect and report on payments made directly to teaching hospitals and indirectly to physicians performing research at the teaching hospital.

Whether used alone or as an integrated component to the FLS platform, ClinSpend provides HCPs access to real-time, proactive dispute resolution through its site portal to review and challenge payment claims made by applicable manufacturers. Manufacturers can proactively manage HCP relationships by verifying data and resolving discrepancies shortly after payment is made, rather than requiring the HCP to wait to file a dispute months later when data are transmitted to CMS.

Clinverse’s application programming interface (API) provides the flexibility for ClinSpend to easily accept research, non-research, and ownership data from a wide variety of additional sources, including clinical software applications and spreadsheets. One example is the recent strategic partnership agreement with Aggregate Spend Solutions, LLC, integrating the company’s flagship product, SpendMD™. SpendMD is a web-based system created to report transfer of value (TOV) associated with investigator and other meeting-related expenses. Related data are captured and easily exportable for review by the client and investigator, and are then sent to ClinSpend to be packaged with all other OPEN PAYMENTS data for submission to CMS.

“The reality is that the cost of meeting these new requirements is a burden and must be absorbed by drug, biologic, device, and manufacturers doing business in the US,” said Steve Ayala, President of Clinverse. “For many manufacturers, managing the volume of data needed for the Sunshine Act will require either a small army of resources or an automated solution. Outsourcing the data collection and integration process to a single, quality-driven solution like ClinSpend is an attractive, cost-effective alternative that allows manufacturers to focus on their core business activities.”

Clinverse will be exhibiting at DIA 2013 in Boston June 23rd – 27th. Stop by Booth #2000 for more information on ClinSpend.

About Clinverse, Inc.
Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Media Contact:
Molly Thompson, Crossroads PR, for Clinverse
919-821-2822
clinverse(at)crossroadspr(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10802333.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
2. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
3. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
4. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
5. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
6. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
7. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
8. JPSA Introduces Picosecond Laser Micromachining System
9. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
10. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
11. White Mountain Process Introduces Squeal-less Mechanical Seal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):